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Purpose: To develop mucoadhesive patches for buccal administration of metoprolol succinate and to 
evaluate their in vitro and in vivo bioadhesion. 
Methods: The mucoadhesive buccal patches were prepared by solvent casting technique using two 
different mucoadhesive polymers. The formulations were tested for in vitro drug permeation studies, 
buccal absorption, in vitro drug release studies, moisture absorption as well as for in vitro and in vivo 
bioadhesion. 
Results: The peak detachment force and work of adhesion for MC5 (sodium carboxymethylcellulose, 
i.e., Na CMC) patch were 0.87 N and 0.451 mJ respectively and the corresponding values for CH5 
(chitosan) were 5.15N and 0.987 mJ. Formulation CH5 (prepared with chitosan) showed 67.1 % 
release, while MC5 (Na CMC) showed drug release of 81.9 % in 6 h. Basic pharmacokinetic parameters 
such as Cmax, Tmax and AUCtotal varied statistically (p < 0.05) when given by the buccal route compared 
with that of the solution given by the oral route.  
Conclusion: The results indicate that formulation of suitable bioadhesive buccal patches with the 
desired permeability is feasible. The development of bioadhesive buccal formulation for metoprolol 
succinate with a lower dose and few side effects may be attainable. 
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INTRODUCTION 
 
Rapid developments in the field of molecular 
biology and gene technology has resulted in 
a generation of many macromolecular drugs 
including peptides, proteins, polysaccharides 
and nucleic acids possessing superior 
pharmacological efficacy, site specificity and 
are devoid of untoward and toxic effects 
However, the main impediment for the oral 
delivery of these drugs is their extensive 
presystemic metabolism and instability in 
acidic environment resulting in inadequate 
and erratic oral absorption [1]. Parenteral 
route of administration is the only established 
route that overcomes these drawbacks. 
However, these formulations are costly, 
require repeated administration and hence 
show poor patient compliance,, in addition to 
the other hazardous effects associated with 
this route [2]. Over the past few decades, 
pharmaceutical scientists have been 
exploring transdermal and transmucosal 
routes as alternative routes to the parenteral 
route. Among the various transmucosal sites 
available, the buccal mucosa has been found 
to be a convenient and easily accessible site 
for the delivery of therapeutic agents for both 
local and systemic delivery because it has an 
expanse of smooth muscle which is relatively 
immobile, abundant vascularization, rapid 
recovery time after exposure to stress and 
the near absence of Langerhans cells. Direct 
access to systemic circulation through the 
internal jugular vein bypasses the hepatic first 
pass metabolism leading to high drug 
bioavailability. Furthermore, these dosage 
forms are self-administrable, low-cost and 
have superior patient compliance [3].  
 
With the right dosage form design, the local 
environment of the mucosa can be controlled 
and manipulated to optimize the rate of drug 
dissolution and permeation. A rational 
approach to dosage form design requires a 
complete understanding of the 
physicochemical and biopharmaceutical 
properties of the drug and excipients. 
Advances in experimental and computational 
methodologies will be helpful in shortening 
the processing time from formulation design 
to clinical use [4].  
 
Metoprolol succinate is a non-selective and 
β-adrenergic antagonist with no intrinsic 
sympatomimetic activity and is widely used to 
treat essential hypertension and angina 
pectoris. Although it is completely absorbed 
from the gastrointestinal tract, systemic 
availability is only approximately 25 – 35 % 
due to first-pass metabolism. Metoprolol 
succinate was selected as a model drug for 
the investigation because its oral dose is 25 
mg and half life is 3-4 h. Metoprolol succinate 
is metabolized primarily by aromatic ring 
glucuronidation [5]. Its oxidative metabolites 
are metabolized by conjugation via 
glucronidation and sulfation. A suitable 
buccal drug delivery system should be 
flexible and possess good bioadhesive 
properties so that it can be retained in the 
oral cavity for the desired duration. In 
addition, it should release the drug in a 
predictable manner to elicit the required 
therapeutic response. The objective of this 
study was to prepare mucoadhesive buccal 
patches of metoprolol succinate and evaluate 






Metoprolol succinate was obtained as a gift 
from Aarti Pharmaceuticals, India while 
sodium carboxymethylcellulose and chitosan 
were supplied by Sigma Pvt Ltd, India. The 
plasticizer, propylene glycol, was purchased 
from Merck (Mumbai, India). All the other 
reagents were of analytical grade. 
. 
Tissue preparation  
 
Porcine buccal tissue from pigs was obtained 
from local slaughter house and used within 2 
hours of slaughter. The tissue was stored in 
kerb buffer (pH 7.4) at 4 
o
C after collection. 
The epithelium was separated surgically from 
the underlying connective tissue and 
delipidized by incubation with chloroform: 
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methanol (2:1) at room temperature for 12 - 
72 h, either before or after digestion with 
strong alkali or concentrated acid. The 
delipidized membrane was allowed to 
equilibrate for approximately one hour in 
receptor buffer (kerb buffer) to regain the lost 
elasticity. 
 
In vitro drug permeation studies 
 
The buccal epithelium was carefully mounted 
in between the two compartments of a Franz 
diffusion cell with internal diameter of 1.0 cm 
with a receptor compartment volume of 20.0 
ml. A solution containing 20 ml of alcohol, 
propylene glycol and phosphate buffer (pH 
6.8) in a ratio of 40:15:45 was placed in the 
receptor compartment. The donor 
compartment (5 ml capacity) contained 
phenol red at a concentration of 10 µg/ml and 
a solution of 3 ml of phosphate buffer pH 6.8 
in which 2 mg of metoprolol succinate was 
dissolved. Phenol red served as a marker 
that would not permeate the porcine buccal 
membrane. The entire set up was placed in a 
water bath stirred by a magnetic stirrer at 37 
± 1 °C. 
                                                                                                       
A sample (1 ml) was collected at 
predetermined time intervals from the 
receptor compartment and replaced with an 
equal volume of fresh receptor fluid [6]. The 
experiment was conducted in triplicate. 
 
Production of bioadhesive films 
 
The films were prepared by casting [7]. 
Aqueous solution (20 ml) of the polymer 
(either sodium CMC or chitosan), ranging 
from a polymer concentration of 1 – 6 %w/v, 
was prepared and left for 4 h for maximum 
swelling; 5 %w/v of propylene glycol (1 ml) 
was added as plasticizer. Metoprolol 
succinate solution (1 ml, 2 %w/v) was mixed 
with 20 ml of the polymer solution and cast in 
a Petri dish 30 min later. It was dried at room 
temperature (25 
o
C) for 12 h. The films were 
observed and checked for possible 
imperfections upon their removal from the 
Petri dish and dried in a desiccator pending 
evaluation. The films were examined in order 
to select those with the best characteristics 
for further evaluation.  
 
In vitro release study  
 
Drug release from the buccal patches was 
studied using USP type II dissolution test 
apparatus [8]. Patches (10 mm diameter) 
were cut, and an impermeable backing 
membrane on one side of the patch. The 
assembly for release studies was prepared 
by placing the patch in contiguity with 
cellulose acetate dialysis membrane such 
that the drug release from the patch diffuses 
through dialysis membrane. This assembly 
was placed in dissolution apparatus 
containing 500 ml of phosphate buffer (pH 
6.8) and rotating at 50 rpm at 37 ± 0.5 
0
C. 
Samples (5 ml) were collected at different 
time intervals and diluted with phosphate 
buffer (pH 6.8), 2 ml of which was analysed 
spectrophotometrically (UV-1800, Shimadzu, 
Japan) at 222 nm [9]. The experiment was 
performed in triplicate. 
 
Moisture uptake/Swelling index) studies  
 
Moisture uptake gives an indication of the 
ability of the patches to maintain their 
integrity after absorption of moisture. Agar 
dispersion (5 %w/v) was prepared by 
dissolving agar in hot water [10]. The 
dispersion (20 ml) was transferred to a 4-inch 
diameter glass Petri dish and allowed to 
solidify. Six drug-free patches from each 
formulation were selected, weighed and 
placed in a vacuum oven(40 – 45 
o
C) 
overnight prior to the study to remove any 
residual moisture. Each patch was laminated 
on one side with a water-impermeable 
backing membrane of ethyl cellulose, using 
an adhesive, incubated at 37 
0
C for 1 h, and 
reweighed [11]. Moisture uptake was 
calculated as percent change in weight of the 
patch. The experiment was performed in 
triplicate.  
Verma & Chattopadhyay   
Trop J Pharm Res, February2012;11 (1): 12 
Measurement of mechanical properties of 
patches 
 
The mechanical properties of the patches 
were evaluated using a tensile tester 
fabricated in-house with stainless steel and 
has two clamps (one movable and the other 
stationary). A 50 x 10 mm patch, without any 
visual defect, was positioned between the 
two clamps, separated by a distance of 2 cm. 
The lower clamp was held stationary and the 
patch was pulled apart by the upper clamp 
moving at a rate of 2 mm/sec until the patch 
broke. The force and elongation of the film at 
the point the patch broke was recorded 
[12,13]. The tensile strength (T) and 
elongation (E) at break point were calculated 
using Eqs 1 and 2, respectively: 
 
T = F/A ………………………..…………… (1) 
 
where F is the force at break point and A is 
initial cross-sectional area of the test patch.  
          
E = (∆L/L) x (100/A) ……………………….. (2) 
 
where ∆L is increase in length, L is the 
original length and A is the cross-sectional. 
 
In vitro bioadhesive strength 
 
The bioadhesive strength of buccal patches 
was determined using modified equipment. 
Fresh porcine buccal mucosa obtained from 
a slaughter house was kept in simulated 
saliva (28.80 g Na2HPO4 and 11.45 g 
KH2PO4 in 1000 ml of distilled water at pH 
6.8) [12] and secured tightly to a circular 
stainless steel adapter of (diameter, 2.2 cm) 
provided with the equipment. The test buccal 
patch was placed over another cylindrical 
stainless steel adapter of similar diameter 
and mounted on the platform connected to a 
pulley. The buccal patch was fixed to a 
backing membrane with a cycnoacrylate 
adhesive. The upper support was lowered at 
a speed of 0.5 mm/s until contact was made 
with the tissue. At the end of the contact time 
(10 - 15 sec), the upper support was 
withdrawn at a speed of 0.5mm/s to detach 
the membrane from the patch. During the 
test, 100 µl of phosphate buffer (pH 6.8) was 
applied to moisten the porcine buccal 
membrane. The test was conducted at room 
temperature. Peak detachment force, which 
is the force required to detach the buccal 
patch from the tissue was recorded while the 
work of adhesion was determined from the 
area under the force - distance curve [15].  
 
In vivo bioadhesion studies 
 
Eight healthy male rabbits were used in the 
study. The institutional animal ethics 
committee (IAEC)’s permission was obtained 
prior to start the study. (approval no.: 
3/837ac/PH/10). Initially a slight pressure was 
applied with a finger for one minute till the 
patch adhered to the buccal mucosa. The 
rabbits were deprived of food and drinks 
during the test. Residence time of the film on 
buccal mucosa in the oral cavity, which was 
taken as the time for the patch to dislodge 
completely from the buccal mucosa, was 
recorded [16]. 
 
In vitro permeation of metoprolol 
succinate  
 
In vitro permeation of metoprolol succinate 
from a buccal patch (formulation MC4) 
through porcine buccal membrane was 
studied. The buccal membrane was isolated 
and mounted over a Franz diffusion cell 
whose internal diameter was 10 mm and a 
buccal patch, which was fixed to a dialysis 
membrane made up of cellulose (molecular 
weight cutoff, 5000) in order to ensure that 
the patch does not dislodge from the 
membrane during the test [17,18]. The buccal 
patch was sandwiched between the buccal 
mucosa and the dialysis membrane. The 
whole diffusion cell assembly was agitated 
with the aid of a magnetic stirrer at 37 ± 0.5 
o
C. One millilter sample was withdrawn hourly 
and analyzed by spectrophotometrically at 
222 nm.   
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In vivo bioavailability Study 
 
Metoprolol succinate a cardiovascular drug 
may sometimes produce hypotension in 
normal patients that may be difficult to control 
and hence bioavailability studies was 
conducted in an animal model (rabbit). The 
study was approved by the institutional 
ethical committee. Rabbit was used because 
its buccal membrane closely resembles the 
human buccal membrane in structure and 
permeability. Rabbits were housed in 
separate cages. The rabbits selected for the 
study were housed in separate cages and 
had no medication for two weeks prior to the 
study. They were denied food and water 
during the study. The cages of rabbit were 
placed in 18 h light/6 h dark conditions. The 
test patch (MC4), containing 125 mg of the 
drug, was laminated on one side with a water 
impermeable backing layer and fixed to the 
buccal section of the oral cavity with the 
patch side. A gentle pressure was applied 
with a finger for 1 min to ensure good 
adhesion to the mucosa. The rabbits were 
placed on their side on a surgery table, 2 ml 
of blood was collected from the ear vein, 
centrifuged, and the serum separated was 
stored at – 20 
o
C until analysed [19]. The 
rabbits were moved to their cages and blood 
samplings continued at intervals for up to 8 h. 
The drug bioavailability of the patch was 
compared with that of a solution (0.5 ml)  
containing 12.5 mg of metoprolol succinate in 
phosphate buffer administered to the rabbits. 
The drug was not administered in the form of 
tablet because it could not be assured that 
the rabbits would swallow it. Relevant 
pharmacokinetic parameters were 
determined and analysed statistically.  
 
Analysis of serum metoprolol succinate 
 
The quantitative determination of metoprolol 
succinate in rabbit serum was carried out by 
high performance liquid chromatography 
(HPLC, Shimadzu, Japan, SPD-20A detector) 
method at room temperature [20]. Phosphate 
buffer (0.02M, pH 6.8)/acetonitrile (60/40, v/v) 
was used as mobile phase at a flow rate of 1 
ml/min; the injected volume was 10 µl and the 




All the data were statistically analysed by 
Student t-test and one-way ANOVA to 
determine statistical difference between sets 
of data. A probability value of p < 0.05 was 
applied to determine significant difference. 
The software used was SigmaPlot 11 (Systat 




Drug penetration through porcine buccal 
membrane 
 
The cumulative amount of metoprolol 
succinate transported across the buccal 
epithelium is plotted against time in Fig 1. 
Drug permeation was rapid and linear first 4 h 
and then gradually slowed down thereafter.  

























Fig 1: In vitro permeation of petoprolol 
succinate through porcine buccal mucosa 
 
In vitro buccal absorption of metoprolol 
 
Based on computations made, 72 % of the 
drug permeated through the buccal 
membrane in 20 min. The drug was absorbed 
at a rapid rate for the first 5 min, followed by 
a steady permeation rate.  
 
In vitro drug release  
 
The drug release profiles of metoprolol 
succinate from buccal patches are shown in 
Figs 2 and 3. In case of Sodium CMC (MC5) 
81.92% of the drug was released when 
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compared with Chitosan (CH5) from which 
only 67.12% of drug was released. The 
formulation (CH5) with a drug to polymer ratio 
of 1:2.5 was used for the evaluation of drug 
release and bioadhesive properties of the 
patches. The best fit with the highest 
correlation coefficient (r
2
) was shown by the 
Higuchi model model (r
2 
= 0.997), followed by 
first order.  
                                                                                                                                                                 
 
Fig 2: Drug release profile of metoprolol succinate 
buccal patches made with chitosan (♦ = CH-1, □ = 
CH-2, ▲ = CH-3, x = CH-4, ■ = CH-5, o = CH-6) 
                       
 
Fig 3: Drug release profile of metoprolol succinate 
buccal patch containing sodium CMC    (♦ = MC-1, 
□ = MC-2,▲ = MC-3, ■ = MC-4, ¤ = MC-5, o = 
MC-6) 
 
Moisture uptake  
 
The results of moisture absorption studies 
are presented in Table 1. Moisture uptake 
ranged from about 72.3 to 154.1 %w/w for 
patched made with sodium CMC and 61.9 to 
98.2 %w/w for those made with chitosan.  
 
Mechanical properties of films 
 
The results of the mechanical properties 
(tensile strength and elongation at break) are 
presented in Table 1. Statistically significant 
differences were observed among the 
elongation data (p < 0.05).
 
In vitro bioadhesion 
 
The results of the in vitro bioadhesion of  
patches MC5 and CH5 indicate that he peak 
detachment force and work of adhesion of 
the former were 0.87 ± 0.31 N and 0.45 ± 
0.15 mJ, respectively, while for the latter, the 
values were 5.15 ± 0.22  N and 0.99 ± 0.18  
mJ, respectively.  
 
In vivo bioadhesion 
 
The results of in vivo bioadhesion test show 
that CH1 exhibited an appreciable adhesion 
for ~ 1 h CH2 ~ 2 h, and CH3, CH4 and CH5 
~ 3h. None of the patches became detached 
during the respective periods indicated 
above.  
 
In vitro drug permeation through porcine 
buccal membrane 
 
The results indicate that drug permeation 
from the patch evaluated (CH5) was slow but 
steady and that 54.8 % of metoprolol 
succinate permeated through the buccal 
membrane in 8 h.  
 
In vivo drug release from metoprolol 
succinate patch 
 
The pharmacokinetic parameters, namely, 
maximum concentration (Cmax), time to reach 
maximum concentration (Tmax) and AUCtotal 
(relatve bioavailability) for patch CH5 are 
given in Table 2. Plasma concentration of 
metoprolol succinate gradually increased and 
attained maximum of 354.6 ± 12.1 ng/ml in 
approx 6 h; thereafter, drug level declined  
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Table 1: Composition and some physicochemical and mechanical properties of mucoadhesive        























in 6 h (%) 
MC 1 1.0  72.26 6.7±1.3 131.2±1.7 85.2±0.2 
MC 2 2.0  86.54 9.0±0.2 112.0±7.8 84.8±1.5 
MC 3 3.0  100.91 12.7±1.1† 94.1±1.4 80.0±2.3 
MC 4 4.0  124.77 14.3±2.3 85.7±4.8 82.5±3.9 
MC 5 5.0  136.02 15.1±1.9†    81.9±0.5 
MC 6 6.0  154.12 16.7±1.3 62.7±2.3 81.8±1.2 
CH 1  1.0 61.88 3.3±1.9 40.5±1.3† 68.9±4.1 
CH 2  2.0 67.50 7.2±0.2 36.9±4.3 68.9±0.7 
CH 3  3.0 76.00 10.1±1.1 29.8±2.2 67.9±3.5 
CH 4  4.0 81.26 11.7±1.7† 20.5±5.3 67.6±0.8 
CH 5  5.0 90.44 12.9±2.3† 14.4±0.3† 67.1±2.5 
CH 6  6.0 98.16 13.2±0.2 11.1±2.1 67.0±0.1 
Note: Each formulation contained 2 %w/v metoprolol succinate and 5%w/v propylene glycol 
 
gradually. The pharmacokinetic parameters 
of metoprolol succinate after the application 
of buccal patch significantly differed from that 
of the oral solution. Unlike oral form, drug 
concentration after application of the buccal 
patch was largely steady over a period of 10 
h. This contrasts with the oral solution that 
showed a Cmax of 254.6 ± 24.4 ng/ml  within 4 
h and declined slowly after 8 h. The AUCtotal 
for the buccal patch was significantly (p < 
0.005) higher than that of the oral solution, 
indicating improved bioavailability for the 
buccal patch (Table 2).  
 
Table 2: Pharmacokinetics of metoprolol succinate 
administered via oral and buccal routes 
 
Route Cmax Tmax (h) AUC total 
(ng.hr/ml) 
Oral 254.6±24.4 4.0±0.7 2007.2±4.7 




The porcine buccal membrane tissue was 
isolated successfully as evidenced by the fact 
that there was no detectable level of phenol 
red (the marker used) in the receptor 
compartment whereas metoprolol succinate 
penetrated freely. The results in vivo 
absorption data for the buccal patch also 
revealed that metoprolol succinate 
penetrated through the oral cavity and that 
the animal did not swallow the solution of the 
drug.  
 
For the patch containing chitosan (CH), drug 
release was governed by polymer content. 
No lag time was observed as the patch was 
directly exposed to the dissolution medium. 
Increase in polymer content correlated with 
decrease in drug release rate. However, 
there was no significant difference between 
the patches with regard to cumulative drug 
released. This may be due to the fact that for 
all the formulations, the drug dissolved 
completely in the dissolution medium. 
Patches made with chitosan exhibited lower 
swelling than those made with Na CMC and 
this might be responsible for the lower drug 
release from the lower. 
 
Tensile strength increased with increase in 
polymer content but elongation at break 
decreased as polymer content rose. The 
pattern was similar for patches made with 
either chitosan or Na CMC. 
 
Metoprolol succinate was adequately 
released from the patches and permeated 
through the porcine buccal membrane and 
could therefore permeate through the human 
buccal membrane. The in vivo data for the 
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buccal patches of metoprolol succinate 
indeed confirmed this as the bioavailability of 
the drug actually increased. A mean oral 
bioavailability of of 25 % has previously been 
reported for metoprolol succinate [21]. In 
contrast, the buccal patch used in the present 
study showed 60 % bioavailability. This 
increase in bioavailability may be due to the 
elimination of hepatic first-pass metabolism 
for drugs given by buccal route. This probably 
also accounts for the prolonged steady-state 





Buccal patches containing 5 % chitosan 
(CH5) demonstrated optimal characteristics 
of the various chitosan concentrations 
evaluated. Buccal delivery of metoprolol 
succinate in patch form in rabbits showed 
superior bioavailability over the oral route. 
The results for these animals may not be 
substantially different from those for humans 
since the structure and permeability of the 
buccal membrane of rabbits is similar to 
those of humans. Thus, the development of a 
bioadhesive buccal patch of metoprolol 
succinate holds some promise since it will 
lead to decreased dosing frequency and 
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